Science & Technology Review
|
2023, 41(1): 131-135
• Exclusive: Science and Technology Review in 2022 •
Hotspots of cancer immunology in 2022: A review
Full
HUANG Bo1, ZHANG Yi2
Affiliations
1. Department of Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
2. Biotherapy Center of the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Published: 2023-01-13
doi: 10.3981/j.issn.1000-7857.2023.01.008
Outline
Tumor immunotherapy has become the fourth type of tumor therapies after surgery, radiotherapy and chemotherapy, and a hot field of international research. Nowadays, we have entered the era of tumor immunotherapy, and immunotherapy represented by immune checkpoint inhibitors and genetically engineered immune cells is a promising therapy for cancers. This article summarizes the hot topics and key advances in cancer immunotherapy in 2022, including the breakthrough of chimeric antigen receptor T cells (CAR-T) in the treatment of solid tumors, the discovery of a new mechanism to maintain survival and function of memory T cells, the in-depth exploration of tumor immunosuppressive microenvironment to improve the efficacy of immunotherapy, and the important influence of intratumoral microbiota on immune responses against tumor.
tumor immunity
/
CAR-T cells
/
memory T cells
/
tumor immunosuppressive microenvironment
/
intratumoral microbiota
HUANG Bo, ZHANG Yi.
Hotspots of cancer immunology in 2022: A review[J].
Science & Technology Review,
2023
, 41
(1)
: 131
-135
.
DOI: 10.3981/j.issn.1000-7857.2023.01.008
Year 2023 volume 41 Issue 1
PDF
628
94
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2023.01.008
- Receive Date:2022-12-19
- Online Date:2023-02-10
- Published:2023-01-13